Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
OBJECTIVES Silodosin is a novel drug that is highly selective to subtype alpha 1A and , since 2006 , has been used in Japan for treating benign prostatic hyperplasia . This study aim ed to compare the clinical effects of the alpha-adrenoceptor antagonist , silodosin , with those of naftopidil in patients presenting lower urinary tract symptoms associated with benign prostatic hyperplasia . METHODS This was a r and omized , open-label , controlled multicenter study carried out in Japan . Overall , 121 participants with lower urinary tract symptoms associated with benign prostatic hyperplasia were r and omized to receive silodosin ( 4 mg twice daily ) or naftopidil ( 50 mg once daily ) for 4 or 8 weeks . Patients were divided into four groups : the alpha-blocker-naive groups received silodosin ( 35 patients ) or naftopidil ( 33 patients ) and the drug-switching groups changed from tamsulosin to silodosin ( 26 patients ) or naftopidil ( 27 patients ) . The outcomes parameters were the International Prostate Symptom Score , quality of life , maximum urinary flow rate and post-void residual urine volume . P < 0.05 was considered statistically significant by using the Wilcoxon signed-rank and rank-sum tests , and analysis of covariance . RESULTS In all the groups , silodosin and naftopidil significantly improved the total International Prostate Symptom Score and quality of life . However , silodosin obtained significantly better improvement in total International Prostate Symptom Score in the alpha-blocker-naive patients at 4 and 8 weeks . The maximum urinary flow rate and residual urine did not change significantly in all the treatment groups . CONCLUSIONS The present study confirms the clinical usefulness of silodosin in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .